These Analysts Boost Their Forecasts On Spotify After Q3 Earnings

Spotify Technology SA (NYSE: SPOT) reported a profit for the third quarter.

Spotify Technology SA (NYSE:SPOT) reported a profit for the third quarter.

Spotify reported third-quarter FY23 revenue growth of 11% year-on-year to €3.36 billion ($3.65 billion), beating the consensus of $3.34 billion. EPS of €0.33 or $0.36 beat the consensus loss of $(0.22).

Spotify said it sees fourth-quarter revenue of €3.7 billion (consensus $3.91 billion), which includes a 300 bps hit from forex.

Spotify shares fell 5.5% to trade at $161.28 on Wednesday.

These analysts made changes to their price targets on Spotify following earnings announcement.

  • Raymond James increased the price target on Spotify from $170 to $180. Raymond James analyst Andrew Marok maintained an Outperform rating.
  • Keybanc raised the price target on Spotify from $205 to $210. Keybanc analyst Justin Patterson maintained an Overweight rating on the stock.
  • Morgan Stanley boosted the price target on Spotify from $190 to $200. Morgan Stanley analyst Manan Gosalia maintained an Overweight rating.
  • Benchmark raised the price target on Spotify from $195 to $202. Benchmark analyst Mark Zgutowicz maintained a Buy rating.
  • Barclays increased the price target on Spotify from $182 to $186. Barclays analyst Mario Lu maintained an Overweight rating.
  • Truist Securities boosted the price target on Spotify from $176 to $190. Truist Securities analyst Matthew Thornton maintained a Buy rating.

Also Check This Out: Alphabet To Rally Over 33%? Here Are 10 Top Analyst Forecasts For Wednesday

Total
0
Shares
Related Posts
Read More

Arrowhead Pharmaceuticals Earns $50M Milestone From Royalty Pharma, Pursuant To Its 2016 Agreement With Amgen And 2022 Agreement With Royalty Pharma, Arrowhead Is Further Eligible To Receive Up To An Additional $375M From Amgen And $110M From Royalty P…

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced a $50 million milestone payment was received from Royalty Pharma plc (NASDAQ:RPRX). This milestone was triggered after the completion of enrollment of the

AMGN